ESMO 2024: Keytruda-Chemo Combination Enhances Survival in Early Triple-Negative Breast Cancer
Significant Findings from the ESMO 2024 Congress
Patients with early-stage triple-negative breast cancer demonstrated improved survival outcomes after treatment with perioperative (time around surgery) Keytruda (pembrolizumab) with chemotherapy, followed by Keytruda after surgery, according to a presentation at the 2024 ESMO Congress.
Key Data from the KEYNOTE-522 Study
Findings from the phase 3 KEYNOTE-522 study were presented, which showed that the perioperative Keytruda-chemotherapy combination reduced the risk of death by 34%, compared with patients who received placebo plus chemotherapy.
- The study revealed that the Keytruda regimen led to improved survival outcomes.
- At a median follow-up of 75.1 months, a five-year OS rate of 86.6% was achieved in the Keytruda-chemotherapy group, compared to 81.7% in the placebo group.
- Patients receiving Keytruda achieved a pCR rate of 64.8%, which is significant compared to 51.2% in the placebo group.
Impact of Keytruda on Early Triple-Negative Breast Cancer
In July 2021, the FDA approved Keytruda plus chemotherapy as a neoadjuvant treatment. Updated efficacy analysis maintained significant improvement in event-free survival rates.
- Five-year EFS rates were 81.2% for the Keytruda group compared to 72.2% for the placebo group.
- OS benefits were evident for those who achieved a pCR in both groups.
Trial Participation Criteria
Eligible patients enrolled in the trial must have been at least 18 years old with newly diagnosed, nonmetastatic triple-negative breast cancer. Participation criteria included adequate organ function and an ECOG performance status of 0 or 1.
Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.